Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Aprea Therapeutics Reports Phase 3 Trial Of Eprenetapopt In TP53 Mutant Myelodysplastic Syndromes Failed To Meet Primary Endpoint


Benzinga | Dec 28, 2020 08:00AM EST

Aprea Therapeutics Reports Phase 3 Trial Of Eprenetapopt In TP53 Mutant Myelodysplastic Syndromes Failed To Meet Primary Endpoint






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC